Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate

Ayesha Ahmad, Stephen G. Kahler, Priya S. Kishnani, Merce Artigas-Lopez, Anuradha Pappu, Robert Steiner, David S. Millington, Johan L K Van Hove

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

A patient with severe pyruvate carboxylase deficiency presented at age 11 weeks with metabolic decompensation after routine immunization. She was comatose, had severe lactic acidemia (22 mM) and ketosis, low aspartate and glutamate, elevated citrulline and proline, and mild hyperammonemia. Head magnetic resonance imaging showed subdural hematomas and mild generalized brain atrophy. Biotin-unresponsive pyruvate carboxylase deficiency was diagnosed. To provide oxaloacetate, she was treated with high-dose citrate (7.5 mol/kg-1/day-1), aspartate (10 mmol/kg-1/day-1), and continuous drip feeding. Lactate and ketones diminished dramatically, and plasma amino acids normalized, except for arginine, which required supplementation. In the cerebrospinal fluid (CSF), glutamine remained low and lysine elevated, showing the treatment had not normalized brain chemistry. Metabolic decompensations, triggered by infections or fasting, diminished after the first year. They were characterized by severe lactic and ketoacidosis, hypernatremia, and a tendency to hypoglycemia. At age 3 1/2 years she has profound mental retardation, spasticity, and grand mal and myoclonic seizures only partially controlled by anticonvulsants. The new treatment regimen has helped maintain metabolic control, but the neurological outcome is still poor.

Original languageEnglish (US)
Pages (from-to)331-338
Number of pages8
JournalAmerican Journal of Medical Genetics
Volume87
Issue number4
DOIs
StatePublished - 1999

Fingerprint

Pyruvate Carboxylase Deficiency Disease
Ketosis
Aspartic Acid
Citric Acid
Brain Chemistry
Milk
Hypernatremia
Hyperammonemia
Oxaloacetic Acid
Citrulline
Subdural Hematoma
Coma
Biotin
Ketones
Glutamine
Hypoglycemia
Proline
Intellectual Disability
Anticonvulsants
Lysine

Keywords

  • Anaplerotic role
  • Aspartate
  • Citrate
  • Neurological outcome
  • Pyruvate carboxylase
  • Treatment

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. / Ahmad, Ayesha; Kahler, Stephen G.; Kishnani, Priya S.; Artigas-Lopez, Merce; Pappu, Anuradha; Steiner, Robert; Millington, David S.; Van Hove, Johan L K.

In: American Journal of Medical Genetics, Vol. 87, No. 4, 1999, p. 331-338.

Research output: Contribution to journalArticle

Ahmad, Ayesha ; Kahler, Stephen G. ; Kishnani, Priya S. ; Artigas-Lopez, Merce ; Pappu, Anuradha ; Steiner, Robert ; Millington, David S. ; Van Hove, Johan L K. / Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. In: American Journal of Medical Genetics. 1999 ; Vol. 87, No. 4. pp. 331-338.
@article{552422a250a247e496f75d458d7f971f,
title = "Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate",
abstract = "A patient with severe pyruvate carboxylase deficiency presented at age 11 weeks with metabolic decompensation after routine immunization. She was comatose, had severe lactic acidemia (22 mM) and ketosis, low aspartate and glutamate, elevated citrulline and proline, and mild hyperammonemia. Head magnetic resonance imaging showed subdural hematomas and mild generalized brain atrophy. Biotin-unresponsive pyruvate carboxylase deficiency was diagnosed. To provide oxaloacetate, she was treated with high-dose citrate (7.5 mol/kg-1/day-1), aspartate (10 mmol/kg-1/day-1), and continuous drip feeding. Lactate and ketones diminished dramatically, and plasma amino acids normalized, except for arginine, which required supplementation. In the cerebrospinal fluid (CSF), glutamine remained low and lysine elevated, showing the treatment had not normalized brain chemistry. Metabolic decompensations, triggered by infections or fasting, diminished after the first year. They were characterized by severe lactic and ketoacidosis, hypernatremia, and a tendency to hypoglycemia. At age 3 1/2 years she has profound mental retardation, spasticity, and grand mal and myoclonic seizures only partially controlled by anticonvulsants. The new treatment regimen has helped maintain metabolic control, but the neurological outcome is still poor.",
keywords = "Anaplerotic role, Aspartate, Citrate, Neurological outcome, Pyruvate carboxylase, Treatment",
author = "Ayesha Ahmad and Kahler, {Stephen G.} and Kishnani, {Priya S.} and Merce Artigas-Lopez and Anuradha Pappu and Robert Steiner and Millington, {David S.} and {Van Hove}, {Johan L K}",
year = "1999",
doi = "10.1002/(SICI)1096-8628(19991203)87:4<331::AID-AJMG10>3.0.CO;2-K",
language = "English (US)",
volume = "87",
pages = "331--338",
journal = "American Journal of Medical Genetics, Part A",
issn = "1552-4825",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate

AU - Ahmad, Ayesha

AU - Kahler, Stephen G.

AU - Kishnani, Priya S.

AU - Artigas-Lopez, Merce

AU - Pappu, Anuradha

AU - Steiner, Robert

AU - Millington, David S.

AU - Van Hove, Johan L K

PY - 1999

Y1 - 1999

N2 - A patient with severe pyruvate carboxylase deficiency presented at age 11 weeks with metabolic decompensation after routine immunization. She was comatose, had severe lactic acidemia (22 mM) and ketosis, low aspartate and glutamate, elevated citrulline and proline, and mild hyperammonemia. Head magnetic resonance imaging showed subdural hematomas and mild generalized brain atrophy. Biotin-unresponsive pyruvate carboxylase deficiency was diagnosed. To provide oxaloacetate, she was treated with high-dose citrate (7.5 mol/kg-1/day-1), aspartate (10 mmol/kg-1/day-1), and continuous drip feeding. Lactate and ketones diminished dramatically, and plasma amino acids normalized, except for arginine, which required supplementation. In the cerebrospinal fluid (CSF), glutamine remained low and lysine elevated, showing the treatment had not normalized brain chemistry. Metabolic decompensations, triggered by infections or fasting, diminished after the first year. They were characterized by severe lactic and ketoacidosis, hypernatremia, and a tendency to hypoglycemia. At age 3 1/2 years she has profound mental retardation, spasticity, and grand mal and myoclonic seizures only partially controlled by anticonvulsants. The new treatment regimen has helped maintain metabolic control, but the neurological outcome is still poor.

AB - A patient with severe pyruvate carboxylase deficiency presented at age 11 weeks with metabolic decompensation after routine immunization. She was comatose, had severe lactic acidemia (22 mM) and ketosis, low aspartate and glutamate, elevated citrulline and proline, and mild hyperammonemia. Head magnetic resonance imaging showed subdural hematomas and mild generalized brain atrophy. Biotin-unresponsive pyruvate carboxylase deficiency was diagnosed. To provide oxaloacetate, she was treated with high-dose citrate (7.5 mol/kg-1/day-1), aspartate (10 mmol/kg-1/day-1), and continuous drip feeding. Lactate and ketones diminished dramatically, and plasma amino acids normalized, except for arginine, which required supplementation. In the cerebrospinal fluid (CSF), glutamine remained low and lysine elevated, showing the treatment had not normalized brain chemistry. Metabolic decompensations, triggered by infections or fasting, diminished after the first year. They were characterized by severe lactic and ketoacidosis, hypernatremia, and a tendency to hypoglycemia. At age 3 1/2 years she has profound mental retardation, spasticity, and grand mal and myoclonic seizures only partially controlled by anticonvulsants. The new treatment regimen has helped maintain metabolic control, but the neurological outcome is still poor.

KW - Anaplerotic role

KW - Aspartate

KW - Citrate

KW - Neurological outcome

KW - Pyruvate carboxylase

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0032732587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032732587&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-8628(19991203)87:4<331::AID-AJMG10>3.0.CO;2-K

DO - 10.1002/(SICI)1096-8628(19991203)87:4<331::AID-AJMG10>3.0.CO;2-K

M3 - Article

C2 - 10588840

AN - SCOPUS:0032732587

VL - 87

SP - 331

EP - 338

JO - American Journal of Medical Genetics, Part A

JF - American Journal of Medical Genetics, Part A

SN - 1552-4825

IS - 4

ER -